Cross-linked nanoparticles of silk fibroin with proanthocyanidins as a promising vehicle of indocyanine green for photo-thermal therapy of glioma

Abstract

(2019) Cross-linked nanoparticles of silk fibroin with proanthocyanidins as a promising vehicle of indocyanine green for photo-thermal therapy of glioma,

Indocyanine Green Nanoparticles: Are They Compelling for Cancer Treatment?

“…Recently, the development of multifunctional ICG-NPs, offering both diagnostic and therapeutic solutions in cancer, has captured the attention of researchers (Han et al, 2018 ). To overcome the limitations previously discussed, several ICG-NPs have been proposed and tested, both in vitro and in vivo (Liu et al, 2019b ; ZhuGe et al, 2019 ), displaying increased circulation time and improved ICG optical properties and achieving tumor-specific accumulation. Many advantages derive from their use: combining or encapsulating it to/into NPs results in the extension of ICG half-life.…”

“…Additionally, functionalization with specific cancer-related antibodies may result in preferential accumulation of ICG at the tumor site. Furthermore, ICG-NPs may be useful to limit ICG aggregation and photodegradation as well as to improve its stability in aqueous solutions (Ishizawa et al, 2009 ; Liu et al, 2019c ; ZhuGe et al, 2019 ). ICG has been loaded or conjugated to a variety of nanostructures, such as polymer-based NPs, lipid-based NPs, and silica NPs with different surface modifications and functionalization strategies ( Figure 1A ).…”

“…PDT is an emerging, minimally invasive cancer treatment based on the production of ROS in response to a source of light, the presence of oxygen and a photosensitizer (i.e., ICG) (ZhuGe et al, 2019 ). Although this option seems promising for many cancers (Gross et al, 2003 ; Ritch and Punnen, 2017 ), selective delivery of the photosensitizers at target tissues/cells remains insufficient for successful clinical use (Zhen et al, 2013 ).…”

Nanoparticles for Stem Cell Therapy Bioengineering in Glioma

“…2019; Shi et al, 2019;Sousa et al, 2019;Ye et al, 2019;Zhang et al, 2019;Zhao et al, 2019;ZhuGe et al, 2019;Alves et al, 2020;Caban-Toktas et al, 2020;Chung et al, 2020;Ferreira et al, 2020;Kazmi et al, 2020;Liang et al, 2020;Martinez-Rovira et al, 2020;Meng et al, 2020;Roberts et al, 2020;Ullah et al, 2020;Wang H. et al, 2020;Wang X. et al, 2020;Xu et al, 2020;Zhu et al, 2020; see Table 3 for examples of ligand targeting in glioma research). Another active targeting method to increase functional specificity of NPs that are used as gene delivery systems is the transcriptional targeting, which can occur at a transcriptional or posttranscriptional level (Golombek et al, 2018).…”

“…Here, the delivered gene includes a tumor-specific promoter (highly functional only in cancer cells), which will secure a well-localized expression of the transgene, limited to occur only inside the cancer cells of interest. Posttranscriptional regulations of the product encoded by the exogenously delivered gene are achieved by controlling RNA splicing, RNA stability, and initiation of the RNA translation once it is present in the cancer cell (Maier-Hauff et al, 2007;Kim et al, 2010;Wegscheid et al, 2014;Cheng Y. et al, 2016;Shen et al, 2017;Yu et al, 2017;Hua et al, 2018;Daniel et al, 2019;Denora et al, 2019;Dufort et al, 2019;Kunoh et al, 2019;Luque-Michel et al, 2019;Ruan et al, 2019;Rego et al, 2019Rego et al, , 2020Shi et al, 2019;Sousa et al, 2019;Ye et al, 2019;Zhang et al, 2019;Zhao et al, 2019;ZhuGe et al, 2019;Alves et al, 2020;Caban-Toktas et al, 2020;Chung et al, 2020;Ferreira et al, 2020;Kazmi et al, 2020;Liang et al, 2020;Martinez-Rovira et al, 2020;Meng et al, 2020;Roberts et al, 2020;Ullah et al, 2020;Wang H. et al, 2020;Wang X. et al, 2020;Xu et al, 2020;Zhu et al, 2020).…”